Robert H Press1,2, Roshan S Prabhu3, Dana C Nickleach4, Yuan Liu4, Hui-Kuo G Shu1,2, Shravan Kandula1,2, Kirtesh R Patel1,2, Walter J Curran1,2, Ian Crocker1,2. 1. Department of Radiation Oncology, Emory University, Atlanta, Georgia. 2. Winship Cancer Institute, Emory University, Atlanta, Georgia. 3. Southeast Radiation Oncology Group, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina. 4. Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: The purpose of this study was to evaluate predictors of early distant brain failure (DBF) and salvage whole-brain radiotherapy (WBRT) after treatment with stereotactic radiosurgery (SRS) for brain metastases and create a clinically relevant risk score to stratify patients' risk for these events. METHODS: The records of 270 patients with brain metastases who were treated with SRS between 2003 and 2012 were reviewed. Pretreatment patient and tumor characteristics were analyzed with univariate and multivariate analyses. The cumulative incidences of first DBF and salvage WBRT were calculated. Significant factors were used to create a score for stratifying early (6-month) DBF risk. RESULTS: No prior WBRT, a total lesion volume < 1.3 cm(3), primary breast cancer or malignant melanoma histology, and multiple metastases (≥2) were found to be significant predictors of early DBF. Each factor was ascribed 1 point because of similar hazard ratios. Scores of 0 to 1, 2, and 3 to 4 were considered to indicate low, intermediate, and high risk, respectively. This correlated with 6-month cumulative incidences of DBF of 16.6%, 28.8%, and 54.4%, respectively (P < .001). For patients without prior WBRT, the 6-month cumulative incidence of salvage WBRT was 2%, 17.7%, and 25.7%, respectively (P < .001). CONCLUSIONS: Early DBF after SRS requiring salvage WBRT remains a significant clinical problem. Patient stratification for early DBF can better inform the decision for the initial treatment strategy for brain metastases. The provided risk score may help to predict early DBF and subsequent salvage WBRT if SRS is initially used. External validation is needed before clinical implementation.
BACKGROUND: The purpose of this study was to evaluate predictors of early distant brain failure (DBF) and salvage whole-brain radiotherapy (WBRT) after treatment with stereotactic radiosurgery (SRS) for brain metastases and create a clinically relevant risk score to stratify patients' risk for these events. METHODS: The records of 270 patients with brain metastases who were treated with SRS between 2003 and 2012 were reviewed. Pretreatment patient and tumor characteristics were analyzed with univariate and multivariate analyses. The cumulative incidences of first DBF and salvage WBRT were calculated. Significant factors were used to create a score for stratifying early (6-month) DBF risk. RESULTS: No prior WBRT, a total lesion volume < 1.3 cm(3), primary breast cancer or malignant melanoma histology, and multiple metastases (≥2) were found to be significant predictors of early DBF. Each factor was ascribed 1 point because of similar hazard ratios. Scores of 0 to 1, 2, and 3 to 4 were considered to indicate low, intermediate, and high risk, respectively. This correlated with 6-month cumulative incidences of DBF of 16.6%, 28.8%, and 54.4%, respectively (P < .001). For patients without prior WBRT, the 6-month cumulative incidence of salvage WBRT was 2%, 17.7%, and 25.7%, respectively (P < .001). CONCLUSIONS: Early DBF after SRS requiring salvage WBRT remains a significant clinical problem. Patient stratification for early DBF can better inform the decision for the initial treatment strategy for brain metastases. The provided risk score may help to predict early DBF and subsequent salvage WBRT if SRS is initially used. External validation is needed before clinical implementation.
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Lincy S Lal; Stacey DaCosta Byfield; Eric L Chang; Luisa Franzini; Lesley-Ann Miller; Rebecca Arbuckle; Liezl Reasonda; Chun Feng; Andrea Adamus; John Michael Swint Journal: Am J Clin Oncol Date: 2012-02 Impact factor: 2.339
Authors: Stephen M Sawrie; Barton L Guthrie; Sharon A Spencer; Robert A Nordal; Ruby F Meredith; James M Markert; Gretchen A Cloud; John B Fiveash Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-04 Impact factor: 7.038
Authors: Samuel T Chao; Gene H Barnett; Michael A Vogelbaum; Lilyana Angelov; Robert J Weil; Gennady Neyman; Alwyn M Reuther; John H Suh Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: R A Patchell; P A Tibbs; W F Regine; R J Dempsey; M Mohiuddin; R J Kryscio; W R Markesbery; K A Foon; B Young Journal: JAMA Date: 1998-11-04 Impact factor: 56.272
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Diandra N Ayala-Peacock; Albert Attia; Steve E Braunstein; Manmeet S Ahluwalia; Jaroslaw Hepel; Caroline Chung; Joseph Contessa; Emory McTyre; Ann M Peiffer; John T Lucas; Scott Isom; Nicholas M Pajewski; Rupesh Kotecha; Mark J Stavas; Brandi R Page; Lawrence Kleinberg; Colette Shen; Robert B Taylor; Nasarachi E Onyeuku; Andrew T Hyde; Daniel Gorovets; Samuel T Chao; Christopher Corso; Jimmy Ruiz; Kounosuke Watabe; Stephen B Tatter; Gelareh Zadeh; Veronica L S Chiang; John B Fiveash; Michael D Chan Journal: J Neurooncol Date: 2017-08-21 Impact factor: 4.130
Authors: Rachel F Shenker; Emory R McTyre; Glen B Taksler; Ralph B D'Agostino; Christina K Cramer; Jimmy Ruiz; Natalie K Alphonse-Sullivan; Michael Farris; Kounosuke Watabe; Fei Xing; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Clin Neurol Neurosurg Date: 2018-11-13 Impact factor: 1.876
Authors: Michael C LeCompte; Emory McTyre; Adrianna Henson; Michael Farris; Catherine Okoukoni; Christina K Cramer; Pierre Triozzi; Jimmy Ruiz; Kounosuke Watabe; Hui-Wen Lo; Michael T Munley; Adrian W Laxton; Stephen B Tatter; Xiaobo Zhou; Michael Chan Journal: Cureus Date: 2017-12-11
Authors: Roshan S Prabhu; Robert H Press; Danielle M Boselli; Katherine R Miller; Scott P Lankford; Robert J McCammon; Benjamin J Moeller; John H Heinzerling; Carolina E Fasola; Kirtesh R Patel; Anthony L Asher; Ashley L Sumrall; Walter J Curran; Hui-Kuo G Shu; Stuart H Burri Journal: J Neurooncol Date: 2017-12-07 Impact factor: 4.130
Authors: Deborah C Marshall; Logan P Marcus; Teddy E Kim; Brandon A McCutcheon; Steven J Goetsch; Takao Koiso; John F Alksne; Kenneth Ott; Bob S Carter; Jona A Hattangadi-Gluth; Masaaki Yamamoto; Clark C Chen Journal: J Neurooncol Date: 2016-03-07 Impact factor: 4.130
Authors: Brahma D Natarajan; Christel N Rushing; Michael A Cummings; Jessica Ms Jutzy; Kingshuk R Choudhury; Michael J Moravan; Peter E Fecci; Justus Adamson; Steven J Chmura; Michael T Milano; John P Kirkpatrick; Joseph K Salama Journal: J Radiosurg SBRT Date: 2019
Authors: Ali Rae; Daniel Gorovets; Paul Rava; Daniel Ebner; Deus Cielo; Timothy J Kinsella; Thomas A DiPetrillo; Jaroslaw T Hepel Journal: Adv Radiat Oncol Date: 2016-08-24